LENZ Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über LENZ Therapeutics Inc Unternehmen

LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

LENZ Therapeutics Inc Informationen



BörsenkürzelLENZ

Name des UnternehmensLENZ Therapeutics Inc

IPO-datumJun 25, 2021

CEOMr. Evert (Eef) Schimmelpennink

Anzahl der mitarbeiter42

WertpapierartOrdinary Share

GeschäftsjahresendeJun 25

Addresse- -

Stadt- -

BörseNASDAQ Global Select Consolidated

Land- -

Postleitzahl- -

Telefon- -

Website- -

BörsenkürzelLENZ

IPO-datumJun 25, 2021

CEOMr. Evert (Eef) Schimmelpennink

Führungskräfte von LENZ Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. James Mccollum

Independent Director

620.60K

--

Mr. Marc Odrich

Chief Medical Officer

99.60K

--

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

+42.00%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

3.19K

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Ms. Shelley B. Thunen

Independent Director

--

Dr. Frederic (Fred) Guerard, Pharm.D.

Independent Director

--

Jeff W. George

Independent Chairman of the Board

--

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. James Mccollum

Independent Director

620.60K

--

Mr. Marc Odrich

Chief Medical Officer

99.60K

--

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

+42.00%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

3.19K

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Sun, Aug 24

Aktionäre

Aktionärstypen

Aktionäre

Anteil

RA Capital Management, LP

14.65%

Alpha Wave Global, LP

12.66%

Versant Ventures

10.10%

Ridgeback Capital Management, L.P.

6.84%

Paradigm BioCapital Advisors LP

6.02%

Andere

49.72%

Aktionäre

Anteil

RA Capital Management, LP

14.65%

Alpha Wave Global, LP

12.66%

Versant Ventures

10.10%

Ridgeback Capital Management, L.P.

6.84%

Paradigm BioCapital Advisors LP

6.02%

Andere

49.72%

Aktionärstypen

Aktionäre

Anteil

Venture Capital

38.62%

Hedge Fund

27.55%

Investment Advisor

23.95%

Investment Advisor/Hedge Fund

14.32%

Individual Investor

2.73%

Research Firm

2.25%

Bank and Trust

0.14%

Pension Fund

0.06%

Insurance Company

0.02%

Institutionelle Beteiligung



Aktualisiert: Sun, Oct 5

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

261

30.52M

107.02%

+1.08M

2025Q2

245

29.52M

104.44%

-639.13K

2025Q1

245

28.95M

104.22%

-285.84K

2024Q4

225

27.65M

100.55%

-350.42K

2024Q3

204

26.43M

96.17%

-1.73M

2024Q2

197

25.06M

103.06%

+4.18M

2024Q1

204

22.41M

93.92%

+12.70M

2023Q4

200

7.73M

92.24%

-2.14M

2023Q3

200

7.54M

90.13%

-2.49M

2023Q2

212

7.64M

91.96%

-2.29M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

RA Capital Management, LP

4.18M

14.65%

--

Jun 30, 2025

Alpha Wave Global, LP

3.61M

12.66%

--

Jun 30, 2025

Versant Ventures

2.88M

10.1%

-135.30K

-4.48%

Sep 18, 2025

Ridgeback Capital Management, L.P.

1.95M

6.84%

--

Apr 14, 2025

Paradigm BioCapital Advisors LP

1.72M

6.02%

+297.23K

+20.93%

Jun 30, 2025

The Vanguard Group, Inc.

1.29M

4.52%

+91.53K

+7.65%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.27M

4.44%

+216.45K

+20.60%

Jun 30, 2025

Adage Capital Management, L.P.

1.12M

3.94%

+585.00K

+108.79%

Jun 30, 2025

72 Investment Holdings, LLC

1.02M

3.57%

--

Jun 30, 2025

Sectoral Asset Management Inc.

977.25K

3.43%

--

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Sun, Nov 2

Name

Anteil

SPDR S&P Pharmaceuticals ETF

1.7%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.28%

Virtus LifeSci Biotech Clinical Trials ETF

1.14%

Invesco Dorsey Wright Healthcare Momentum ETF

0.75%

Invesco Dorsey Wright SmallCap Momentum ETF

0.43%

iShares U.S. Pharmaceuticals ETF

0.34%

iShares Micro-Cap ETF

0.16%

Invesco Nasdaq Biotechnology ETF

0.14%

ProShares Ultra Nasdaq Biotechnology

0.14%

iShares Biotechnology ETF

0.11%

SPDR S&P Pharmaceuticals ETF

Anteil1.7%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Anteil1.28%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil1.14%

Invesco Dorsey Wright Healthcare Momentum ETF

Anteil0.75%

Invesco Dorsey Wright SmallCap Momentum ETF

Anteil0.43%

iShares U.S. Pharmaceuticals ETF

Anteil0.34%

iShares Micro-Cap ETF

Anteil0.16%

Invesco Nasdaq Biotechnology ETF

Anteil0.14%

ProShares Ultra Nasdaq Biotechnology

Anteil0.14%

iShares Biotechnology ETF

Anteil0.11%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Datum

Art

Verhältnis

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1